Patient autonomy and the regulation of direct-to-consumer advertising

Zachry, Woodie M.; Ginsburg, Diane B.

doi:10.1016/s0149-2918(01)80155-7

Cited by 17 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consumers trusted advertisements with side-effect information more than advertisements focusing on the drug benefits. This finding is consistent with studies examining consumers' perspectives regarding DTCA of prescription drugs in the United States [35,36]. More than half of consumers had positive opinions about DTCA for prescription drugs, but the remaining consumers had neutral or negative opinions about the necessity of DTCA.…”

Section: Discussionsupporting

confidence: 88%

Direct-to-consumer advertising (DTCA) for prescription drugs: Consumers’ attitudes and preferences concerning its regulation in South Korea

Suh¹,

Lee²,

Kim³

et al. 2011

Health Policy

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Direct-to-consumer advertising (DTCA) for prescription drugs: Consumers’ attitudes and preferences concerning its regulation in South Korea

Suh¹,

Lee²,

Kim³

et al. 2011

Health Policy

View full text Add to dashboard Cite

“…As Woodie Zachry and Diane Ginsburg pointed out, however, few studies examine the actual effects of DTC advertising. 7 In one of these studies, John Calfee and colleagues examined whether the 1997 FDA policy change increased the demand for statins but were unable to find any significant direct effect. 8 There are also studies that examined DTC advertising, using survey data.…”

mentioning

confidence: 99%

How Direct-To-Consumer Television Advertising For Osteoarthritis Drugs Affects Physicians’ Prescribing Behavior

Bradford

Kleit²,

Nietert³

et al. 2006

Health Affairs

View full text Add to dashboard Cite

Concern about the potential pernicious effect of direct-to-consumer (DTC) drug advertising on physicians' prescribing patterns was heightened with the 2004 withdrawal of Vioxx, a heavily advertised treatment for osteoarthritis. We examine how DTC advertising has affected physicians' prescribing behavior for osteoarthritis patients. We analyzed monthly clinical information on fifty-seven primary care practices during 2000-2002, matched to monthly brand-specific advertising data for local and network television. DTC advertising of Vioxx and Celebrex increased the number of osteoarthritis patients seen by physicians each month. DTC advertising of Vioxx increased the likelihood that patients received both Vioxx and Celebrex, but Celebrex ads only affected Vioxx use. [Health Affairs 25, no. 5 (2006):

show abstract

“…In August 1999, this Guidance got its final form (FDA, 1999). According to Zachry and Ginsburg (2001), by issuing this guidance the FDA acted to protect the consumer, based in part on its own interpretation of what the level of consumers' autonomy should be. Autonomy in this discussion implies 'that a consumer has the capacity to inform oneself, reason, understand, and execute a choice satisfactorily free…”

Section: Us Contextmentioning

confidence: 99%

“…Much has already been written about DTCA and the advantages and disadvantages associated with it, often focusing on issues of patient autonomy and empowerment (Fisher and Ronald, 2008;Zachry and Ginsburg, 2001). 'Proponents of DTC communication emphasize the need for ''patient empowerment'', as a patient has the right to receive accurate and reliable information' (Fabius et al, 2004, p. 169).…”

Section: Introductionmentioning

confidence: 99%

“…Although DTCA is permitted according to US regulations, several directives apply for these advertisements. These directives have mostly been based on a voluntary basis and all contain the expectation that advertisements are sincere and that the contents of these ads provide fair and balanced information on the benefits and risks of therapy (ACP/ASIM, 1998; Zachry and Ginsburg, 2001). The degree of consumer/patient autonomy hence is also restricted as DTCA must offer the consumer an option to choose by providing insight in the available prescription drugs and the way they work.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Direct-to-Consumer Advertising of Pharmaceuticals as a Matter of Corporate Social Responsibility?

Pol

Bakker

2009

J Bus Ethics

View full text Add to dashboard Cite

ABSTRACT. Direct-to-consumer advertising (DTCA) of prescription drugs has been a heavily contested issue over the past decade, touching on several issues of responsibility facing the pharmaceutical industry. Much research has been conducted on DTCA, but hardly any studies have discussed this topic from a corporate social responsibility (CSR) perspective. In this article, we use several elements of CSR, emphasising consumer autonomy and safety, to analyse differences in DTCA practices within two different policy contexts, the United States of America and the European Union (EU). Doing so results in an alternative analysis of the struggle between proponents and opponents of DTCA from a CSR perspective, adding an alternative view on this debate.

show abstract

Patient autonomy and the regulation of direct-to-consumer advertising

Cited by 17 publications

References 21 publications

Direct-to-consumer advertising (DTCA) for prescription drugs: Consumers’ attitudes and preferences concerning its regulation in South Korea

Direct-to-consumer advertising (DTCA) for prescription drugs: Consumers’ attitudes and preferences concerning its regulation in South Korea

How Direct-To-Consumer Television Advertising For Osteoarthritis Drugs Affects Physicians’ Prescribing Behavior

Direct-to-Consumer Advertising of Pharmaceuticals as a Matter of Corporate Social Responsibility?

Contact Info

Product

Resources

About